
    
      This study includes a 1-week screening period, an 8-week (or greater) antihyperglycemic agent
      (AHA) wash-off and/or metformin dose stable period (as necessary), a 2-week single-blind
      placebo run-in period, a 26-week double-blind treatment period, and a post-treatment
      telephone contact 14 days after the last dose of study drug.
    
  